Cyclooxygenase II: A molecular target for colorectal cancer prevention and treatment?

Annals of Cancer Research and Therapy

Volumn 15, Issue 1, 2007, Pages 14-21

  Yoshimatsu, Kazuhiko ^a   Yamaguchi, Kentaro ^a   Otani, Taisuke ^a   Aizawa, Masaki ^a   Ogawa, Kenji ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemoprevention; Colorectal cancer; COX 2 inhibitor; Cyclooxygenase 2 (COX 2); Microsomal prostaglandin E synthase 1 (mPGES 1)

Indexed keywords

EID: 76349106890     PISSN: 13446835     EISSN: None     Source Type: Journal    
DOI: 10.4993/acrt.15.14     Document Type: Review

References (102)

1. Thun, M.J., Namboodiri, M.M., Heath, C.W. Jr. (1991) Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325: 1593-1596.
2. Thun, M.J., Namboodiri, M.M., Calle, E.E., Flanders, W.D., Heath, C.W. Jr. (1993) Aspirin use and risk of fatal colon cancer. Cancer. Res. 53: 1322-1327.
3. Giovannucci, E., Rimm, E.B., Stampfer, M.J., Colditz, G.A., Ascherio, A., Willett, W.C. (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121: 241-246.
4. Giovannucci, E., Egan, K.M., Hunter, D.J., Stampfer, M.J., Colditz, G.A., Willett, W.C., Speizer, F.E. (1995) Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333: 609-614.
5. Narisawa, T., Satoh, M., Sano, M., Takahashi, T. (1983) Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis. 4: 1225-1227.
6. Narisawa, T., Takahashi, M., Niwa, M., Fukaura, Y., Wakizaka, A. (1987) Involvement of prostaglandin E2 in bile acid-caused promotion of colon carcinogenesis and anti-promotion by the cyclooxygenase inhibitor indomethacin. Jpn. J. Cancer. Res. 78: 791-798.
7. Yamaguchi, A., Ishida, T., Nishimura, G., Katoh, M., Miyazaki, I. (1991) Investigation of colonic prostaglandins in carcinogenesis in the rat colon. Dis. Colon. Rectum. 34: 572-576.
8. Levy GN. (1997) Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB. J. 11: 234-247.
9. Chan, G., Boyle, J.O., Yang, E.K., Zhang, F., Sacks, P.G., Shah, J.P., Edelstein, D., Soslow, R.A., Koki, A.T., Woerner, B.M., Masferrer, J.L., Dannenberg, A.J. (1999) Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer. Res. 59: 991-994.
10. Rolland, P.H., Martin, P.M., Jacquemier, J., Rolland, A.M., Toga, M. (1980) Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer. Inst. 64: 1061-1070.
11. Bennett, A., Charlier, E.M., McDonald, A.M., Simpson, J.S., Stanford, I.F., Zebro, T. (1977) Prostaglandin and breast cancer. Lancet ii: 624-626.
12. Parrett, M.L., Harris, R.E., Joarder, F.S., Ross, M.S., Clausen, K.P., Robertson, F.M. (1997) Cyclooxygenase-2 expression in human breast cancer. Int. J. Oncol. 10: 503-507.
13. Huang, M., Stolina, M., Sharma, S., Mao, J., Zhu, L., Miller, P., Wollman, J., Herschman, H., Dubinett, S. (1998) Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin-10 and down-regulation of interleukin-12 production. Cancer. Res. 58: 1208-1216.
14. Hida, T., Yatabe, Y., Achiwa, H., Muramatsu, H., Kozaki, K.I., Nakamura, S., Ogawa, M., Mitsudomi, T., Sugiura, T., Takahashi, T. (1998) Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer. Res. 58: 3761-3764.
15. Wolf, H., Saukkonen, K., Anttila, S., Karjalainen, A., Vainio, H., Ristimaki, A. (1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer. Res. 58: 4997-5001.
16. Koga, H., Sakisaka, S., Ohishi. M., Kawaguchi, T., Taniguchi, E., Sasatomi, K., Harada, M., Kusaba, T., Tanaka, M., Kimura, R., Nakashima, Y., Nakashima, O., Kojiro, M., Kurohiji, T., Sata, M. (1999) Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology. 29: 688-696.
17. Shiota, G., Okubo, M., Noumi, T., Noguchi, N., Oyama, K., Takano, Y., Yashima, K., Kishimoto, Y., Kawasaki, H. (1999) Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology. 46:407-412.
18. Kondo, M., Yamamoto, H., Nagano, H., Okami, J., Ito, Y., Shimizu, J., Eguchi, H., Miyamoto, A., Dono, K., Umeshita, K., Matsuura, N., Wakasa, K,. Nakamori, S., Sakon, M., Monden, M. (1999) Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer. Res. 5:4005-4012.
19. Kulkarni, S., Rader, J.S., Zhang, F., Liapis, H., Koki, A.T., Masferrer, J.L., Subbaramaiah, K., Dannenberg, A.J. (2001) Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer. Res. 7: 429-434.
20. Ishiko, O., Sumi, T., Yoshida, H., Tokuyama, O., Wakasa, K., Haba, T., Ogita, S. (2001) Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix. Oncol. Rep. 8: 1023-1025.
21. Sales, K.J., Katz, A.A., Davis, M., Hinz, S., Soeters, R.P., Hofmeyr, M.D., Millar, R.P., Jabbour, H.N. (2001) Cyclooxygenase-2 expression and prostaglandin E2 synthesis are up-regulated in carcinomas of the cervix: A possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J. Clin. Endocrinol. Metab. 86: 2243-2249.
22. Golijanin, D., Tan, J.Y., Kazior, A., Cohen, E.G., Russo, P., Dalbagni, G., Auborn. K.J., Subbaramaiah, K., Dannenberg, A.J. (2004) Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin. Cancer Res. 10: 1024-1031.
23. Reddy, B.S., Maruyama, H., Kelloff, G. (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer. Res. 47: 5340-5346.
24. Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J.M., Evans J.F., Taketo, M.M. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87: 803-809.
25. McCormic, D.L., Moon, R.C. (1983) Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal anti-inflammatory agent. Br. J. Cancer. 48: 859-861.
26. McCormic, D.L., Madigan, M.J., Moon, R.C. (1985) Modulation of rat mammary carcinogenesis by indomethacin. Cancer. Res. 45: 1803-1808.
27. Cornwall, H., Odukoya, O., Shklar, G. (1983) Oral mucosal tumor inhibition by ibuprofen. Oral. Maxillofac. Surg. 41: 795-800.
28. Castonguay, A., Rioux, N. (1997) Inhibition of lung tumorigenesis by sulindac: Comparison of two experimental protocols. Carcinogenesis, 18: 491-496,
29. Kerins, D.M., Murray, R., FitzGerald, G.A. (1991) Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility. Prog. Hemost. Thromb. 10: 307-337.
30. Funk, C.D., Funk, L.B., Kennedy, M.E., Pong, A.S., Fitzgerald, G.A. (1991) Human platelet/ erythroleukemia cell prostaglandin G/H synthase: DNA cloning, expression, and gene chromosomal assignment. FASEB. J. 5: 2304-2312.
31. Kosaka, T., Miyata, A., Ihara, H., Hara, S., Sugimoto, T., Takeda, O., Takahashi, E., Tanabe, T. (1994) Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase-2. Eur. J. Biochem. 221: 889-897.
32. Subbaramaiah, K., Telang N., Ramonetti, J.Y., Araki, R., DeVito, B., Weksler, B.B., Dannenberg, A.J. (1996) Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer. Res. 56: 4424-4429.
33. Herschman, H.R. (1996) Prostaglandin synthase 2. Biochem. Biophys. Acta. 1299: 125-140.
34. Inoue, H., Yokoyama, C., Hara, S., Tone, Y., Tanabe, T. (1995) Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J. Biol. Chem. 270: 24965-24971.
35. Subbaramaiah, K., Norton, L., Gerald, W., Dannenberg, A.J. (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 277:18649-18657.
36. Kurumbail, R.G., Stevens, A.M., Gierse, J.K., McDonald, J.J., Stegeman, R.A., Pak, J.Y., Gildehaus, D., Miyashiro, J.M., Penning, T.D., Seibert, K., Isakson, P.C., Stallings, W.C. (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 384: 644-648.
37. Rigas, B., Goldman, I.S., Levine, L. (1993) Altered eicosanoid levels in human colon cancer. J. Lab, Clin. Med. 122: 518-523.
38. Yang, V.W., Shields, J.M., Hamilton, S.R., Spannhake, E.W., Hubbard, W.C., Hylind, L.M., Robinson, C.R., Giardiello, F.M. (1998) Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer. Res. 58: 1750-1753.
39. Murakami, M., Naraba, H., Tanioka, T., Semmyo, N., Nakatani, Y., Kojima, F., Ikeda, T., Fueki, M., Ueno, A., Oh, S., Kudo, I. (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandinE2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 275: 32783-32792.
40. Jakobsson, P.J., Thoren, S., Morgenstern, R., Samuelsson, B. (1999)Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target Proc. Natl. Acad. Sci. USA. 96: 7220-7225.
41. Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M., Kudo, I. (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in mediated prostaglandin E2 biosynthesis. J. Biol. Chem. 275: 32775-32782.
42. Yoshimatsu, K., Golijanin, D., Paty, P.B., Soslow, R.A., Jakobsson, P.J., DeLellis, R.A., Subbaramaiah, K., Dannenberg, A.J. (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer. Res. 7: 3971-3976.
43. Yoshimatsu, K., Altorki, N.K., Golijanin, D., Zhang, F., Jakobsson, P.J., Dannenberg, A.J., Subbaramaiah, K. (2001) Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer. Res. 7: 2669-2674.
44. Cohen, E.G., Almahmeed, T., Du, B., Golijanin, D., Boyle, J.O., Soslow, R.A., Subbaramaiah, K., Dannenberg, A.J. (2003) Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin. Cancer. Res. 9: 3425-3430.
45. Jang, T.J. (2004) Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis. Virchows. Arch. 445: 564-571.
46. Mehrotra, S., Morimiya, A., Agarwal, B., Konger, R., Badve, S. (2006) Microsomal prostaglandin E (2) synthase-1 in breast cancer: a potential target for therapy. J Pathol. 208: 356-363.
47. Takeda, H., Sonoshita, M., Oshima, H., Sugihara, K., Chulada, P.C., Langenbach, R., Oshima, M., Taketo, M.M. (2003) Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer. Res. 63: 4872-4877.
48. Tsujii, M., DuBois, R.N. (1998) Alterations in cellular adhesion and apoptosis in epithelial cells overexpression prostaglandin endoperoxide synthase-2. Cell. 83: 493-501.
49. Sheng, H., Shao, J., Morrow, J.D. (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58: 362-366.
50. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., DuBois, R.N. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93: 705-716.
51. Tsujii, M., Kawano, S., DuBois, R.N. (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA. 94: 3336-3340.
52. Baich, C.M., Doghert, P.A., Cloud, G.A. (1984) Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery. 95: 71-77.
53. Kambayashi, T., Alexander, A.R., Fong, M. (1995) Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26 derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J. Immunol. 154: 3383-3390.
54. Castonguay, A., Rioux, N. (1997) Inhibition of lung tumorigenesis by sulindac: Comparison of two experimental protocols. Carcinogenesis. 18: 491-496.
55. Boolbol, S.K., Dannenberg, A.J., Chadburn, A., Martucci, C., Guo, X.J., Ramonetti, J.T., Abreu-Goris, M., Newmark, H.L., Lipkin, M.L., DeCosse, J.J., Bertagnolli, M.M. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer. Res. 56: 2556-2560.
56. Sales, K.J., Maudsley, S., Jabbour, H.N. (2004) Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3′,5′-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways. Mol. Endocrinol. 18:1533-1545.
57. Spinella, F., Rosano, L., DiCastro, V., Natali, P.G., Bagnato, A. (2004) Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J. Biol. Chem. 279: 46700-46705.
58. Aggarwal, S., Taneja, N., Lin, L., Orringer, M.B., Rehemtulla, A., Beer, D.G. (2000) Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia. 2: 346-356.
59. Vogt, T., McClelland, M., Jung, B., Popova, S., Bogenrieder, T., Becker, B., Rumpler, G., Landthaler, M., Stolz, W. (2001) Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma. Res. 11: 587-599.
60. Smith, M.L., Hawcroft, G., Hull, M.A. (2000) The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur. J. Cancer. 36: 664-674.
61. Hanif, R., Pittas, A., Feng, Y., Koutsos, M.I., Qiao, L., Staiano-Coico, L., Shiff, S.I., Rigas, B. (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52: 237-245.
62. Waskewich, C., Blumenthal, R.D., Li, H., Stein, R., Goldenberg, D.M., Burton, J. (2002) Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer. Res. 62: 2029-2033.
63. Elder, D.J., Halton, D.E., Hague, A., Paraskeva, C. (1997) Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer. Res. 3: 1679-1683.
64. Richter, M., Weiss, M., Weinberger, I., Furstenberger, G., Marian, B. (2001) Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis. 22: 17-25.
65. Song, X., Lin, H.P., Johnson, A.J., Tseng, P.H., Yang, Y.T., Kulp, S.K., Chen, C.S. (2002) Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer. Inst. 94:585-591.
66. Zhang, X., Morham, S.G., Langenbach, R., Young, D.A. (1999) Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190: 451-459.
67. Williams, C.S., Watson, A.J., Sheng, H., Helou, R., Shao, J., DuBois, R.N. (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer. Res. 60: 6045-6051.
68. Nagatsuka, I., Yamada, N., Shimizu, S., Ohira, M., Nishino, H., Seki, S., Hirakawa, K. (2002) Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int. J. Cancer. 100: 515-519.
69. Yamauchi, T., Watanabe, M., Hasegawa, H., Nishibori, H., Ishii, Y., Tatematsu, H., Yamamoto, K., Kubota, T., Kitajima, M. (2003) The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Anticancer. Res. 23: 245-249.
70. Tomozawa, S., Nagawa, H., Tsuno, N., Hatano, K., Osada, T., Kitayama, J., Sunami, E., Nita, M.E., Ishihara, S., Yano, H., Tsuruo, T., Shibata, Y., Muto, T. (1999) Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer. 81: 1274-1279.
71. Yao, M., Lam, E.C., Kelly, C.R., Zhou, W., Wolfe, M.M. (2004) Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br. J. Cancer. 90: 712-719.
72. Nishikawa, M., Stapleton, P.P., Freeman, T.A., Gaughan, J.P., Matsuda, T., Daly, J.M. (2004) NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. J. Am. Coll. Surg. 199: 428-435.
73. Yao, M., Kargman, S., Lam, E.C., Kelly, C.R., Zheng, Y., Luk, P., Kwong, E., Evans, J.F., Wolfe, M.M. (2003) Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer. Res. 63: 586-592.
74. Fenwick, S.W., Toogood, G.J., Lodge, J.P., Hull, M.A. (2003) The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology. 125: 716-729.
75. Chen, W.S., Wei, S.J., Liu, J.M., Hsiao, M., Kou-Lin, J., Yang, W.K. (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int. J. Cancer. 91: 894-899.
76. Matsunaga, N., Yamada, N., Ohira, M., Tachimori, A., Nishiguchi, Y., Nishino, H., Seki, S., Hirakawa, K. (2004) Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. Oncol. Rep. 11: 167-171.
77. Ishizaki, T., Katsumata, K., Tsuchida, A., Wada, T., Mori, Y., Hisada, M., Kawakita, H., Aoki, T. (2006) Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int. J. Mol. Med. 17: 357-362.
78. Steinbach, G., Lynch, P.M., Phillips, R.K., Wallace. M.H., Hawk. E., Gordon, G.B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L.K., Levin, B. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342: 1946-1952.
79. Higuchi, T., Iwama, T., Yoshinaga, K., Toyooka, M., Taketo, M.M., Sugihara, K. (2003) A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin. Cancer. Res. 9: 4756-4760.
80. Cruz-Correa, M., Hylind, L.M., Romans, K.E., Booker, S.V., Giardiello, F.M. (2002) Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology. 122: 641-645.
81. Lynch, H.T., Thorson, A.G., Smyrk, T. (1995) Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer. 75: 936-938.
82. Niv, Y., Fraser, G.M. (1994) Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology. 107: 854-857.
83. Keller, J.J., Offerhaus, G.J., Drillenburg, P., Caspers, E., Musler, A., Ristimaki, A., Giardiello, F.M. (2001) Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin. Cancer. Res. 7: 4000-4007.
84. Giardiello, F.M., Yang, V.W., Hylind, L.M., Krush, A.J., Petersen, G.M., Trimbath, J.D., Piantadosi, S., Garrett, E., Geiman, D.E., Hubbard, W., Offerhaus, G.J., Hamilton, S.R. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. 346: 1054-1059.
85. Bertagolli, M.M., Eagle, C.J., Zauber, A.G., Redston, M., Solomon, S.D., Kim, K.M., Tang, J., Rosenstein, R.B., Wittes, J., Corle, D., Hess, T.M., Woloj, M., Boisserie, F., Anderson, W.F., Viner, J.L., Bagheri, D., Burn, J., Chung, D.C., Dewar, T., Foley, T.R., Hoffman, N., Macrae, F., Pruitt, R.E., Saltzman, J.R., Salzberg, B., Sylwestrowicz, T., Gordon, G.B., Hawk, E.T. (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355: 873-884.
86. Arber, N., Eagle, C.J., Spicak, J., Racz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M.J., Gerletti, P., Tang, J., Rosenstein, R.B., Macdonald, K., Bhadra, P., Fowler, R., Wittes, J., Zauber, A.G., Solomon, S.D., Levin, B.; PreSAP Trial Investigators (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 3559: 885-95.
87. Baron, J.A., Sandler, R.S., Bresalier, R.S., Quan, H., Riddell, R., Lanas, A., Bolognese, J.A., Oxenius, B., Horgan, K., Loftus, S., Morton, D.G.; APPROVe Trial Investigators. (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 131: 1674-1682.
88. Silverstein, F.E., Faich, G., Goldstein, J.L., Simon, L.S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N.M., Stenson, W.F., Burr, A.M., Zhao, W.W., Kent, J.D., Lefkowith, J.B., Verburg, K.M., Geis, G.S. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 284: 1247-1255.
89. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K., Schnitzer, T.J.; VIGOR Study Group. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343: 1520-1528.
90. Bresalier, R.S., Sandler, R.S., Quan, H., Bolognese, J.A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M.A., Baron, J.A., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352: 1092-1102.
91. Fries, S., Grosser, T., Price, T.S., Lawson, J.A., Kapoor, S., Demarco, S., Pletcher, M.T., Wiltshire, T., Fitzgerald, G.A. (2006) Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology. 130: 55-64
92. Cheng, Y., Wang, M., Yu, Y., Lawson, J., Funk, C.D., FitzGerald, G.A. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. (2006) J. Clin. Invest. 116: 1391-1399.
93. Backlund, M.G., Mann, J.R., Holla, V.R., Buchanan, F.G., Tai, H.H., Musiek, E.S., Milne, G.L., Katkuri, S., DuBois, R.N. (2005) 15- Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 280: 3217-3223.
94. Yan, M., Rerko, R.M., Platzer, P., Dawson, D., Willis, J., Tong, M., Lawrence, E., Lutterbaugh, J., Lu, S., Willson, J.K., Luo, G., Hensold, J., Tai, H.H., Wilson, K., Markowitz, S.D. (2004) 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc. Natl. Acad. Sci. USA. 101: 17468-17473.
95. Myung, S.J., Rerko, R.M., Yan, M., Platzer, P., Guda, K., Dotson, A., Lawrence, E., Dannenberg, A.J., Lovgren, A.K., Luo, G., Pretlow, T.P., Newman, R.A., Willis, J., Dawson, D., Markowitz, S.D. (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl. Acad. Sci. USA. 103:12098-12102.
96. Sheng, H., Shao, J., Washington, M.K., DuBois, R.N. (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 276: 18075-18081.
97. Sonoshita, M., Takaku, K., Sasaki, N., Sugimoto, Y., Ushikubi, F., Narumiya, S., Oshima, M., Taketo, M.M. (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc (Delta 716) knockout mice. Nat. Med. 7: 1048-1051.
98. Seno, H., Oshima, M., Ishikawa, T.O., Oshima, H., Takaku, K., Chiba, T., Narumiya, S., Taketo, M.M. (2002) Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc (Delta716) mouse intestinal polyps. Cancer. Res. 62:506-511.
99. Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, H., Maruyama, T., Kondo, K., Narumiya, S., Sugimura, T., Wakabayashi, K. (2000) Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer. Lett. 156:57-61.
100. Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, H., Maruyama, T., Kondo, K., Ushikubi, F., Narumiya, S., Sugimura, T., Wakabayashi, K. (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer. Res. 59:5093-5096.
101. Narko, K., Ristimaki, A., MacPhee, M., Smith, E., Haudenschild, C.C., Hla, T. (1997) Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J. Biol. Chem. 272: 21455-21460.
102. Chulada, P.C., Thompson, M.B., Mahler, J.F., Doyle, C.M., Gaul, B.W., Lee, C., Tiano, H.F., Morham, S.G., Smithies, O., Langenbach, R. (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer. Res. 60: 4705-4708.